Renal Graft Function After Treatment With Erythropoietin (EPO)

• Status: Terminated
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Background : Numerous studies have outlined the cellular pleiotropic effects of erythropoietin (EPO) and their role in the prevention of ischemic-reperfusion lesion such as after acute ischemic injury of the brain or the heart. However, most of these studies were carried out in animal models and no definitive proof exists today to demonstrate that EPO has similar beneficial effects in human pathology.

Purpose : The aim of the study is to demonstrate that in humans, EPO can protect against ischemic-reperfusion lesions in a model of ischemia i.e. kidney transplantation.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Limoges
• Collaborator: Hoffmann-La Roche
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• donor:

• cadaveric organ donor,

• age ≥ 18 years,

• mono-organ (kidney) retrieval,

• retrieval done in the centres of Limoges, Bordeaux, Toulouse, Angers, Brest, Nantes, Poitiers, Rennes, Tours,

• hematocrit ≤ 45%.

• Recipient:

• age ≥ 18 years,

• on the waiting list for a kidney graft.

Exclusion Criteria:

• living donors,

• age under 18 years,

• multi-organ retrieval,

• donor hematocrit above 45%